SCHEMBL3873200

SCHEMBL3873200

Clc1[c]c(Cl)c(-c2cccc(Cl)c2Cl)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.37
IDO1 P14902 1/20 0.37
NUDT1 P36639 4/20 0.37
TSHR P16473 1/20 0.35
CYP2D6 P10635 1/20 0.35
MAOA P21397 1/20 0.35
MAPK1 P28482 1/20 0.35
ADRA1A P35348 1/20 0.35
SCN4A P35499 1/20 0.35
BLM P54132 1/20 0.35
PMP22 Q01453 1/20 0.35
PDE3A Q14432 1/20 0.35
SCN5A Q14524 1/20 0.35
SCN9A Q15858 1/20 0.35
SCN2A Q99250 1/20 0.35
SCN3A Q9NY46 1/20 0.35
SCN10A Q9Y5Y9 1/20 0.35
CNR2 P34972 6/20 0.35
P2RX7 Q99572 3/20 0.34
CNR1 P21554 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15637369 0.83 CYP2A6 (0.43) NOTUMIDO1TSHR
SCHEMBL11405846 0.81 IDO1 (0.40) IDO1CNR2
SCHEMBL1815221 0.79 FGFR1 (0.33) TSHR
SCHEMBL440943 0.78 TSHR (0.52) NOTUMIDO1NUDT1TSHRCYP2D6
SCHEMBL15636895 0.73 NOTUM (0.39) NOTUMIDO1NUDT1TSHRCYP2D6
SCHEMBL811508 0.73 AHR (0.50) NOTUMIDO1NUDT1TSHRCYP2D6
SCHEMBL9728771 0.72 TAAR1 (0.34) MAPK1
SCHEMBL11497642 0.71 NUDT1 (0.46) NOTUMIDO1NUDT1TSHRCYP2D6
SCHEMBL381601 0.71 CYP2A6 (0.52) NOTUMIDO1NUDT1TSHRCYP2D6
SCHEMBL29385608 0.71 CYP2A6 (0.52) NOTUMIDO1NUDT1TSHRCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1235595-B8 INTEGRIN-MEDIATED DRUG TARGETING BAYER SCHERING PHARMA AG (DE) 2009-10-07 EP claimed
EP-1235595-A2 INTEGRIN-MEDIATED DRUG TARGETING Bayer Aktiengesellschaft (DE) 2002-09-04 EP claimed
WO-2001017563-A2 INTEGRIN-MEDIATED DRUG TARGETING BAYER AKTIENGESELLSCHAFT (DE) 2001-03-15 WO claimed